Research programme: anti-interleukin monoclonal antibodies - OREGA Biotech

Drug Profile

Research programme: anti-interleukin monoclonal antibodies - OREGA Biotech

Alternative Names: Anti-IL-17B mAbs; IL-17B neutralising antibodies

Latest Information Update: 15 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Orega Biotech
  • Developer INSERM; Institut Godinots; OREGA Biotech
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Interleukin-17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Inflammation

Most Recent Events

  • 18 Apr 2017 OREGA Biotech has patent pending for anti-IL-17 antibodies in USA
  • 01 Apr 2017 Preclinical trials in Inflammation in France (Parenteral) before April 2017
  • 31 Dec 2016 OREGA Biotech has patent protection for anti-IL-17 antibodies in Europe before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top